Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | CYP4Z1 | Q86W10 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 2/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.44 |
| ▸ | LIPE | Q05469 | 1/20 | 0.44 |
| ▸ | AKT1 | P31749 | 1/20 | 0.43 |
| ▸ | IRS1 | P35568 | 1/20 | 0.43 |
| ▸ | GAB1 | Q13480 | 1/20 | 0.43 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.42 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2665963 | 0.85 | LMNA (0.56) | LMNAKDM4EALDH1A1TSHRHSD17B10 | |
| SCHEMBL2665972 | 0.85 | KMT2A (0.57) | LMNAKDM4EALDH1A1TSHRHSD17B10 | |
| SCHEMBL27513611 | 0.85 | CYP1A2 (0.62) | LMNAKDM4EALDH1A1TSHRHSD17B10 | |
| SCHEMBL68851 | 0.84 | CYP4Z1 (0.62) | LMNAKDM4EALDH1A1TSHRHSD17B10 | |
| SCHEMBL184666 | 0.83 | CYP4F2 (0.56) | LMNAKDM4EALDH1A1MAPTGAA | |
| SCHEMBL19781654 | 0.82 | LMNA (0.53) | LMNAKDM4EALDH1A1TSHRHSD17B10 | |
| SCHEMBL2654388 | 0.81 | KMT2A (0.56) | LMNAKDM4EALDH1A1TSHRHSD17B10 | |
| SCHEMBL2520720 | 0.81 | L3MBTL1 (0.58) | LMNAKDM4EALDH1A1TSHRHSD17B10 | |
| SCHEMBL18151834 | 0.81 | ALDH1A1 (0.53) | LMNAKDM4EALDH1A1TSHRHSD17B10 | |
| SCHEMBL2665987 | 0.81 | KMT2A (0.53) | LMNAKDM4EALDH1A1TSHRHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 73 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023202583-A1 | FXR REGULATOR AND USE THEREOF | 北京大学 | 2023-10-26 | — | — | WO | disclosed |
| CN-116903559-A | FXR modulators and uses thereof | 北京大学 | 2023-10-20 | — | — | CN | disclosed |
| US-11084784-B2 | ROR-gamma modulators and uses thereof | Piramal Enterprises Limited (IN) | 2021-08-10 | — | — | US | disclosed |
| EP-3303291-B1 | ROR-GAMMA MODULATORS | LEAD PHARMA B V (NL) | 2020-03-18 | — | — | EP | disclosed |
| EP-3303292-B1 | ROR GAMMA (RORY) MODULATORS | LEAD PHARMA B V (NL) | 2020-03-18 | — | — | EP | disclosed |
| CN-105980353-B | ROR gamma modulators | 领先制药控股公司 | 2019-06-14 | — | — | CN | disclosed |
| US-10315996-B2 | ROR gamma (RORγ) modulators | LEAD PHARMA HOLDING B.V. (NL) | 2019-06-11 | — | — | US | disclosed |
| US-10259782-B2 | ROR gamma (RORγ) modulators | LEAD PHARMA HOLDING B.V. (NL) | 2019-04-16 | — | — | US | disclosed |
| EP-3077372-B1 | ROR GAMMA (RORY) MODULATORS | LEAD PHARMA HOLDING BV (NL) | 2019-02-06 | — | — | EP | disclosed |
| CN-108473429-A | ROR gamma modulators | 领先制药控股公司 | 2018-08-31 | — | — | CN | disclosed |
| WO-2005095418-A1 | SULFONAMIDE-THIAZOLPYRIDINE DERIVATIVES AS GLUCOKINASE ACTIVATORS USEFUL THE TREATMENT OF TYPE 2 DIABETES | NOVARTIS AG (CH) | 2005-10-13 | — | — | WO | disclosed |
| US-20040192708-A1 | Sulfonamide substituted xanthine derivatives | DUNTEN PETER W (US) | 2004-09-30 | — | — | US | disclosed |
| WO-2004074288-A1 | SULFONAMIDE SUBSTITUTED XANTHINE DERIVATIVES FOR USE AS PEPCK INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2004-09-02 | — | — | WO | disclosed |
| WO-2004065389-A1 | PYRROLOPYRIMIDINE DERIVATIVES USEFUL AS MODULATORS OF MULTIDRUG RESISTANCE | XENOVA LIMITED (GB) | 2004-08-05 | — | — | WO | disclosed |
| EP-0811375-B1 | GLUTAMIC ACID RECEPTOR AGONIST | NIPPON SUISAN KAISHA LTD (JP) | 2001-01-03 | — | — | EP | disclosed |
| US-5955505-A | TREATING NERVE DEGENERATIVE DISORDERS | NIPPON SUISAN KAISHA, LTD. (JP) | 1999-09-21 | — | — | US | disclosed |
| EP-0811375-A1 | GLUTAMIC ACID RECEPTOR AGONIST | NIPPON SUISAN KAISHA, LTD. (JP) | 1997-12-10 | — | — | EP | disclosed |
| EP-0469901-B1 | Sulfonamide derivatives | TAISHO PHARMACEUTICAL CO LTD (JP) | 1994-10-19 | — | — | EP | disclosed |
| US-5189211-A | Thromboxane A2 antagonists | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 1993-02-23 | — | — | US | disclosed |
| EP-0469901-A1 | Sulfonamide derivatives | TAISHO PHARMACEUTICAL CO. LTD (JP) | 1992-02-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040192708-A1 | Sulfonamide substituted xanthine derivatives | GYS2, SLC5A1, SLC5A2 | LMNA 4064/4885KDM4E 2503/4885ALDH1A1 277/4885 |
| US-10315996-B2 | ROR gamma (RORγ) modulators | RORA, RORB, RORC | LMNA 4187/4885KDM4E 2199/4885ALDH1A1 605/4885 |
| US-11084784-B2 | ROR-gamma modulators and uses thereof | RORB, RORA, RORC | LMNA 2879/4885KDM4E 4027/4885ALDH1A1 902/4885 |
| US-10259782-B2 | ROR gamma (RORγ) modulators | RORA, RORB, RORC | LMNA 4119/4885KDM4E 2264/4885ALDH1A1 838/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.